Amyotrophic Lateral Sclerosis Market Size was USD 490 Million in 2021, estimates DelveInsight

October 04 20:51 2023
Amyotrophic Lateral Sclerosis Market Size was USD 490 Million in 2021, estimates DelveInsight

“The Amyotrophic Lateral Sclerosis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period (2023-2032). Furthermore, launching various multiple- Amyotrophic Lateral Sclerosis pipeline products will significantly revolutionize the Amyotrophic Lateral Sclerosis market dynamics”

 

The Amyotrophic Lateral Sclerosis market report provides current treatment practices, Amyotrophic Lateral Sclerosis emerging drugs, market share of individual therapies, and current and forecasted 7MM Amyotrophic Lateral Sclerosis market size from 2019 to 2032. The report also covers current Amyotrophic Lateral Sclerosis treatment market practices/algorithms and unmet medical needs to curate the best opportunities and assess the market’s underlying potential.

 

Key Takeaways from the Amyotrophic Lateral Sclerosis Market Research Report

  • The total Amyotrophic Lateral Sclerosis diagnosed prevalent cases in the 7MM and China were 59,130 and 29,095in 2021, growing at a CAGR of 1.3% and 0.6% respectively during the study period (2019–2032).
  • The leading companies working in the Amyotrophic Lateral Sclerosis Market include Helixmith, Sanofi, Denali Therapeutics, Alector, GSK, NeuroSense Therapeutics, Biogen, Ionis, Brainstorm Cell Therapeutics, Cytokinetics, Astellas Pharma, Apellis Pharmaceuticals, Clene Nanomedicine Biosciences, AL-S Pharma, MediciNova, Seelos Theraputics, Prilenia Therapeutics, AB Science, Eledon Pharmaceuticals, Revalesio Corporation, Biohaven Pharmaceuticals, UCB Pharma, Ra Pharmaceuticals, and others.
  • Promising Amyotrophic Lateral Sclerosis Pipeline Therapies in the various stages of development include Reldesemtiv, Albutein 5%, Tofersen, FAB122, sNN0029, ABBV-CLS-7262, SPG302, Dazucorilant 300 mg, and others.
  • September 2023: Ionis Pharmceuticals Inc. announced a study of phase 3 clinical trials for ION363. The primary purpose of this study is to evaluate the clinical efficacy of ION363 on clinical function and survival in carriers of fused in sarcoma mutations with amyotrophic lateral sclerosis (FUS-ALS).
  • September 2023: Sanofi announced a study of phase 2 clinical trials for SAR443820. This is a parallel treatment, Phase 2, randomized, double-blind study to assess the efficacy, safety, tolerability, PK, and PD of twice daily (BID) oral SAR443820 compared with placebo in male and female participants,18 to 80 years of age with ALS followed by an open label, longterm extension period.

 

Discover more about therapies set to grab major Amyotrophic Lateral Sclerosis Market Share @ Amyotrophic Lateral Sclerosis Market Size

 

Amyotrophic Lateral Sclerosis Overview

Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, is a group of rare neurological diseases that mainly involve the nerve cells (neurons) responsible for controlling voluntary muscle movement. The disease is progressive, meaning the symptoms get worse over time. ALS belongs to a wider group of disorders known as motor neuron diseases caused by gradual deterioration (degeneration) and death of motor neurons.

 

Amyotrophic Lateral Sclerosis Epidemiology Segmentation in the 7MM

  • Amyotrophic Lateral Sclerosis Prevalence
  • Amyotrophic Lateral Sclerosis Diagnosed Prevalence
  • Amyotrophic Lateral Sclerosis Gender-specific Distribution
  • Amyotrophic Lateral Sclerosis Mutation-specific Distribution
  • Amyotrophic Lateral Sclerosis Type-specific Distribution
  • Amyotrophic Lateral Sclerosis Distribution based on Site of onset
  • Amyotrophic Lateral Sclerosis Age-specific Distribution

 

Download the report to understand which factors are driving Amyotrophic Lateral Sclerosis Epidemiology Trends @ Amyotrophic Lateral Sclerosis Epidemiological Insights

 

Amyotrophic Lateral Sclerosis Marketed Drugs

  • Radicava (Mitsubishi Tanabe Pharma Corporation)
  • RELYVRIO (AMX0035) Amylyx Pharmaceuticals
  • Exservan (Aquestive Therapeutics)
  • TIGLUTIK/ TEGLUTIK (ITF Pharma)
  • Nuedexta (Avanir Pharmaceuticals)

 

Amyotrophic Lateral Sclerosis Emerging Drugs

  • Tofersen (Biogen/Ionis Pharmaceuticals)
  • ION363 (Ionis Pharmaceuticals)
  • Masitinib (AB Sciences)
  • AIT-101 (LAM-002A) – AI Therapeutics
  • Pridopidine (Prilenia Therapeutics)

 

To know more about Amyotrophic Lateral Sclerosis Treatment options, visit @ Amyotrophic Lateral Sclerosis Drugs

 

Amyotrophic Lateral Sclerosis Market Outlook

Amyotrophic lateral sclerosis (ALS) is a group of rare neurological diseases mainly involving the nerve cells (neurons) responsible for controlling voluntary muscle movement. Voluntary muscles produce movements like chewing, walking, and talking. The disease is progressive, meaning the symptoms get worse over time. The Amyotrophic Lateral Sclerosis treatment landscape includes multidisciplinary care, such as physical therapy, speech therapy, dietary counselling, heat or whirlpool therapy and others. Medications are also prescribed to help manage symptoms of Amyotrophic Lateral Sclerosis, including pain, muscle cramps, stiffness, excess saliva and phlegm, and the pseudobulbar affect (involuntary or uncontrollable episodes of crying and/or laughing, or other emotional displays). Drugs also are available to help individuals with pain, depression, sleep disturbances, and constipation.

 

Amyotrophic Lateral Sclerosis Treatment Market

The Amyotrophic Lateral Sclerosis treatment market continues to evolve, driven by scientific advancements and a growing understanding of the disease. While challenges persist, researchers, clinicians, and advocacy groups worldwide are collaborating to accelerate progress in ALS research and treatment development.

 

Learn more about the Amyotrophic Lateral Sclerosis Pipeline Therapies in clinical trials @ Amyotrophic Lateral Sclerosis Market Landscape

 

Scope of the Amyotrophic Lateral Sclerosis Market Research Report

  • Coverage- 7MM
  • Study Period- 2019-2032
  • Amyotrophic Lateral Sclerosis Companies- Helixmith, Sanofi, Denali Therapeutics, Alector, GSK, NeuroSense Therapeutics, Biogen, Ionis, Brainstorm Cell Therapeutics, Cytokinetics, Astellas Pharma, Apellis Pharmaceuticals, Clene Nanomedicine Biosciences, AL-S Pharma, MediciNova, Seelos Theraputics, Prilenia Therapeutics, AB Science, Eledon Pharmaceuticals, Revalesio Corporation, Biohaven Pharmaceuticals, UCB Pharma, Ra Pharmaceuticals, and others.
  • Amyotrophic Lateral Sclerosis Pipeline Therapies- Reldesemtiv, Albutein 5%, Tofersen, FAB122, sNN0029, ABBV-CLS-7262, SPG302, Dazucorilant 300 mg, and others.
  • Amyotrophic Lateral Sclerosis Market Dynamics: Amyotrophic Lateral Sclerosis Market Drivers and Barriers
  • Amyotrophic Lateral Sclerosis Market Access and Reimbursement, Unmet Needs, and Future Perspectives

 

Discover more about Amyotrophic Lateral Sclerosis Drugs in development @ Amyotrophic Lateral Sclerosis Ongoing Clinical Trials Analysis

 

Table of Content

1. Key Insights

2. Amyotrophic Lateral Sclerosis Market Report Introduction

3. Amyotrophic Lateral Sclerosis Market Overview at a Glance

4. Epidemiology and Market Forecast Methodology

5. Amyotrophic Lateral Sclerosis Executive Summary

6. Key Events

7. Amyotrophic Lateral Sclerosis SWOT Analysis

8. Amyotrophic Lateral Sclerosis Market Disease Background and Overview

9. Amyotrophic Lateral Sclerosis Treatment and Management

10. European Federation of Neurological Societies (EFNS) guidelines on the Clinical Management of ALS (MALS) (2012)

11. American Association of Neurology (AAN) Guidelines for Care and Management of Patients with ALS (2009)

12. Management Algorithm for Respiratory Dysfunction in ALS

13. Management guidelines for ALS in Japan, the United States, and Europe.

14. Epidemiology and Patient Population of the 7MM and China

15. Patient Journey

16. Key Endpoints in Amyotrophic Lateral Sclerosis

17. Amyotrophic Lateral Sclerosis Marketed Drugs

18. Amyotrophic Lateral Sclerosis Emerging Drugs

19. Amyotrophic Lateral Sclerosis: Seven Major Market and China Analysis

20. Amyotrophic Lateral Sclerosis Unmet Needs

21. Amyotrophic Lateral Sclerosis Market Access and Reimbursement

22. Appendix

23. DelveInsight Capabilities

24. Disclaimer

25. About DelveInsight

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Healthcare Market Research Reports, Competitive Landscaping, and Mergers and acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/ci-tracking

  Categories: